Month: August 2020

Stjórn Reita fasteignafélags hf. hefur samþykkt árshlutareikning fyrir fyrstu sex mánuði ársins 2020. Helstu lykiltölur reikningsins eru:Fjárhæðir eru í milljónum króna nema annað sé tekið fram.Hlutföll í rekstarreikningi reiknuð sem hlutfall af heildartekjum.Guðjón Auðunsson, forstjóri:„Áhrifa af Covid-19 gætir í rekstri Reita fyrstu sex mánuði ársins og er líklegt að svo verði áfram um hríð. Áhrifin eru takmörkuð hvað skrifstofu- og iðnaðarhúsnæði varðar en áhrifin urðu augljós fyrir ferðaþjónustuna og verslunarrekstur að hluta, þegar faraldurinn náði fótfestu hér á landi í mars sl. og samkomutakmarkanir voru settar á.Verslunarrekstur náði sér vel á strik  eftir að samkomutakmörkunum var létt í byrjun maí og hefur umfang verslunar í júní til ágúst, t.d. í Kringlunni, verið langt umfram sama tímabil síðasta árs. Hins vegar ríkir enn...

BRENTWOOD, Tenn. , Aug. 24, 2020 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE:  CXW) (the “Company”) a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways, announced today its participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for August 26, 2020.The virtual road show will feature a corporate presentation from CoreCivic President & CEO, Damon Hininger and CFO, David Garfinkle, followed by a Q & A session proctored by Noble Senior Analyst Joe Gomes, featuring questions submitted by the audience.The live broadcast of the virtual road show is scheduled for August 26, 2020, at 2 p.m. EDT.  Registration is free, but limited to 100.  Register Here.About CoreCivicThe Company is a...

Stjórn Norðurslóðar 4 ehf. hefur samþykkt árshlutareikning vegna fyrri árshelmings 2020.Leigutekjur á fyrri árshelmingi 2020 voru 84 millj. kr. (2019: 82 millj. kr.)Rekstrarhagnaður fyrir matsbreytingu (NOI) nam 65 millj. kr. á fyrri árshelmingi (2019: 66 millj. kr.)Matsbreyting fjárfestingareigna nam 6 millj. kr. til lækkunar (2019: 21 millj. kr. til hækkunar)Hagnaður á fyrri helmingi ársins 2020 nam 16 millj. kr. (2019: 36 millj. kr.)Virði fjárfestingareigna var 1.929 millj. kr. þann 30.6.2020 (31.12.2019: 1.935 millj. kr.)Eiginfjárhlutfall félagsins þann 30.6.2020 var 30,2% samanborið við 29,4% í árslok 2019.Upplýsingar um afkomu samstæðunnar má finna á www.reitir.is/fjarfestar. Frekari upplýsingar veitir Einar Þorsteinsson, fjármálastjóri, í síma 669 4416 eða í netfanginu einar@reitir.is.ViðhengiNorðurslóð 4 ehf. árshlutareikningur...

ADLPartnerSociété anonyme à directoire et conseil de surveillance au capital de 6 478 836 euros3, avenue de Chartres 60500 – CHANTILLY393 376 801 R.C.S. CompiègneDéclaration des transactions sur actions propres réalisées du 17 au 21 août 2020Présentation agrégée par jour et par marchéDétail transaction par transactionRelations Investisseurs & Informations financièresTel : +33 1 41 58 72 03 – Courriel : relations.investisseurs@adlpartner.frADLPartner est cotée sur Euronext Paris – Compartiment CCodes ISIN : FR0000062978-ALP – Bloomberg : ALP FP – Reuters : ALDP.PAwww.adlpartner.comPièce jointeADLPartner_rachats_actions_24082020

Paris, France, August 24, 2020 – Nexans 2020 will implement a new employee shareholding plan before the end of the year.This transaction will result in a share capital increase of Nexans company of a maximum five hundred thousand (500,000) shares. The issuance of new shares is scheduled for 13 November 2020.The main terms and conditions of this employee shareholding plan are described hereinafter.PURPOSE OF THE TRANSACTIONThis shareholding plan, which is in line with the policy of developing the employee shareholding within the Group will cover twenty five (25) countries. Nexans wishes to associate closely its employees in France and abroad with the Group’s development.This transaction, called “NEXANS Act 2020”, will consist in a unique offer including a leverage effect and an investment guarantee which could be adjusted according...

Paris, France le 24 août 2020 – Nexans procédera avant la fin de l’année à la mise en œuvre d’une nouvelle opération d’actionnariat salarié.

VANCOUVER, Colombie-Britannique, 24 août 2020 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V : MMY et FSE : D7Q1) (« Monument » ou la « Société ») fait le point sur sa mine d’or de Selinsing entièrement détenue dans l’État de Pahang, en Malaisie.Cathy Zhai, Présidente-directrice générale, a déclaré : « Selinsing est notre principal projet de production aurifère. Nous continuons de travailler dur sur plusieurs alternatives de financement afin de mettre à niveau l’usine de traitement de l’or de Selinsing qui traitera le minerai sulfuré, concrétisant la nouvelle production de la mine. En attendant, notre équipe opérationnelle se concentre également sur la durabilité de la production aurifère pour combler l’écart pendant la conversion, améliorer la conception du projet des sulfures et réaliser des tests...

VANCOUVER, British Columbia (Kanada), Aug. 24, 2020 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY und FSE: D7Q1) („Monument“ oder das „Unternehmen“) veröffentlicht neueste Informationen zur Goldmine Selinsing im Bundesstaat Pahang, Malaysia, die sich zu 100 % im Besitz des Unternehmens befindet.CEO und President Cathy Zhai sagte: „Selinsing ist unser Hauptprojekt im Bereich der Goldproduktion. Wir arbeiten weiterhin intensiv an verschiedenen Finanzierungsalternativen, um die Goldverarbeitungsanlage in Selinsing zu modernisieren, in der Sulfiderz behandelt wird, was eine neue Ära der Produktion in der Mine einläuten wird. In der Zwischenzeit konzentriert sich unser Betriebsteam auch auf die Nachhaltigkeit der Goldproduktion, um die Lücke während der Umstellung zu schließen, das Projektdesign in Hinsicht auf Sulfid zu verbessern...

VANCOUVER, British Columbia, Aug. 24, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is providing the clarification that the recently published report on the Company initiated by Mackie Research Capital Corporation (“Mackie”), is an independent research report and further the Company does not accredit the target share price reported by Mackie. Further, the recommendations and target are the opinions of Mackie and are independent of the Company.This update was provided at the request of the Investment Industry Regulatory Organization of Canada.About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving...